clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2024-102-11-12-824-830clinmed-983Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESПрофилактика тромбозов в онкогинекологииPrevention of thrombosis in gynecological oncologyhttps://orcid.org/0000-0002-7426-9040МельниковА. П.MelnikovA. P.

Мельников Андрей Павлович — канд. мед. наук, врач АФО ГБУЗ МО МОНИИАГ им. акад. В.И. Краснопольского

Москва

Andrey P. Melnikov — Candidate of Medical Sciences, doctor

Moscow

https://orcid.org/0000-0002-1231-167XМосковкинаЕ. И.MoskovkinaE. I.

Московкина Евгения Ивановна — клинический ординатор

Москва

Evgenia I. Moskovkina — clinical resident

Moscow

jane_md@mail.ruhttps://orcid.org/0009-0008-3261-1339ГасановаК. С.GasanovaK. S.

Гасанова Камилла Сулеймановна — клинический ординатор

Москва

Kamilla S. Gasanova — clinical resident

Moscow

ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии» им. академика В.И. КраснопольскогоРоссияV.I. Krasnopolsky Moscow Regional Research Institute of Obstetrics and GynecologyRussian Federation20241003202510211-12824830Copyright © Мельников А.П., Московкина Е.И., Гасанова К.С., 20252025Мельников А.П., Московкина Е.И., Гасанова К.С.Melnikov A.P., Moskovkina E.I., Gasanova K.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/983

В представленном обзоре иностранной литературы затрагивается актуальный вопрос профилактики венозных тромбоэмболических осложнений в практике современных онкогинекологов, подчеркивается связь между тяжестью течения онкологического процесса и частотой тромбоэмболических осложнений, наличие которых предопределяет неблагоприятный исход; обсуждаются методики профилактического применения антикоагулянтов, их место в комплексной терапии и взаимодействие с другими методами проводимого лечения. В данной работе обсуждаются лабораторные методики для определения маркеров онкологических заболеваний и контроля проводимого лечения. Рассматривается перспектива мультидисциплинарного подхода с участием генетиков, иммунологов, биохимиков и специалистов лабораторной диагностики к решению вопросов профилактики и лечения онкогинекологических заболеваний.

This review of foreign literature addresses the pressing issue of preventing venous thromboembolic complications in the practice of modern oncogynecologists. It emphasizes the connection between the severity of the oncological process and the frequency of thromboembolic complications, the presence of which predetermines an unfavorable outcome. The review discusses methods for the prophylactic use of anticoagulants, their role in comprehensive therapy, and their interaction with other treatment methods. This work also discusses laboratory techniques for determining markers of oncological diseases and monitoring the treatment being administered. The prospect of a multidisciplinary approach involving geneticists, immunologists, biochemists, and laboratory diagnostics specialists to address issues of prevention and treatment of oncogynecological diseases is considered.

тромбоэмболические осложнениягинекологическая онкологиялабораторные предикторы тромботических осложненийпрогноз при онкологической патологииthromboembolic complicationsgynecological oncologylaboratory predictors of thrombotic complicationsprognosis in oncological pathologyReferencesZhu Y.W., Feng T.B., Zhou X.J., Hu X.L., Ding J., Zhu W.Y., Qian D.P., Sun Y.W. Routine hemostasis and hemogram parameters: valuable assessments for coagulation disorder and chemotherapy in cancer patients. Chin. Med. J. (Engl). 2016;129(15):1772–7. DOI: 10.4103/0366-6999.186637Zhu Y.W., Feng T.B., Zhou X.J., Hu X.L., Ding J., Zhu W.Y., Qian D.P., Sun Y.W. Routine hemostasis and hemogram parameters: valuable assessments for coagulation disorder and chemotherapy in cancer patients. Chin. Med. J. (Engl). 2016;129(15):1772–7. DOI: 10.4103/0366-6999.186637Ohashi Y., Ikeda M., Kunitoh H., Sasako M., Okusaka T., Mukai H.et al. Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. Jpn. J. Clin. Oncol. 2020;50(11):1246–1253. DOI: 10.1093/jjco/hyaa112Ohashi Y., Ikeda M., Kunitoh H., Sasako M., Okusaka T., Mukai H.et al. Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. Jpn. J. Clin. Oncol. 2020;50(11):1246–1253. DOI: 10.1093/jjco/hyaa112Dring J.C., Forma A., Chilimoniuk Z., Dobosz M., Teresiński G., Buszewicz G. et al. Essentiality of trace elements in pregnancy, fertility, and gynecologic cancers-a state-of-the-art Review. Nutrients. 2021;14(1):185. DOI: 10.3390/nu14010185Dring J.C., Forma A., Chilimoniuk Z., Dobosz M., Teresiński G., Buszewicz G. et al. Essentiality of trace elements in pregnancy, fertility, and gynecologic cancers-a state-of-the-art Review. Nutrients. 2021;14(1):185. DOI: 10.3390/nu14010185Meixner E., Sandrini E., Hoeltgen L., Eichkorn T., Hoegen P., König L., Arians N. et al. Return to work, fatigue and cancer rehabilitation after curative radiotherapy and radiochemotherapy for pelvic gynecologic cancer. Cancers (Basel). 2022;14(9):2330. DOI: 10.3390/cancers14092330Meixner E., Sandrini E., Hoeltgen L., Eichkorn T., Hoegen P., König L., Arians N. et al. Return to work, fatigue and cancer rehabilitation after curative radiotherapy and radiochemotherapy for pelvic gynecologic cancer. Cancers (Basel). 2022;14(9):2330. DOI: 10.3390/cancers14092330Torre L.A., Trabert B., DeSantis C.E., Miller K.D., Samimi G., Runowicz C.D. et al. Ovarian cancer statistics, 2018. CA Cancer J. Clin. 2018;68(4):284–296. DOI: 10.3322/caac.21456Torre L.A., Trabert B., DeSantis C.E., Miller K.D., Samimi G., Runowicz C.D. et al. Ovarian cancer statistics, 2018. CA Cancer J. Clin. 2018;68(4):284–296. DOI: 10.3322/caac.21456Piechocki M., Koziołek W., Sroka D., Matrejek A., Miziołek P., Saiuk N. et al. Trends in incidence and mortality of gynecological and breast cancers in Poland (1980–2018). Clin. Epidemiol. 2022;14:95– 114. DOI: 10.2147/CLEP.S330081Piechocki M., Koziołek W., Sroka D., Matrejek A., Miziołek P., Saiuk N. et al. Trends in incidence and mortality of gynecological and breast cancers in Poland (1980–2018). Clin. Epidemiol. 2022;14:95– 114. DOI: 10.2147/CLEP.S330081Borgfeldt C., Holmberg E., Marcickiewicz J., Stålberg K., Tholander B., Lundqvist E.Å. et al. Survival in endometrial cancer in relation to minimally invasive surgery or open surgery - a Swedish Gynecologic Cancer Group (SweGCG) study. BMC Cancer. 2021;21(1):658. DOI: 10.1186/s12885-021-08289-3Borgfeldt C., Holmberg E., Marcickiewicz J., Stålberg K., Tholander B., Lundqvist E.Å. et al. Survival in endometrial cancer in relation to minimally invasive surgery or open surgery - a Swedish Gynecologic Cancer Group (SweGCG) study. BMC Cancer. 2021;21(1):658. DOI: 10.1186/s12885-021-08289-3Danckwardt S., Hentze M.W., Kulozik A.E. Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. J. Mol. Med. (Berl). 2013;91(11):1257–71. DOI: 10.1007/s00109-013-1074-5Danckwardt S., Hentze M.W., Kulozik A.E. Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. J. Mol. Med. (Berl). 2013;91(11):1257–71. DOI: 10.1007/s00109-013-1074-5Kansuttiviwat C., Niprapan P., Tantiworawit A., Norasetthada L., Rattarittamrong E., Rattanathammethee T. et al. Impact of antiphospholipid antibodies on thrombotic events in ambulatory cancer patients. PLoS One. 2023;18(1):e0279450. DOI: 10.1371/journal.pone.0279450Kansuttiviwat C., Niprapan P., Tantiworawit A., Norasetthada L., Rattarittamrong E., Rattanathammethee T. et al. Impact of antiphospholipid antibodies on thrombotic events in ambulatory cancer patients. PLoS One. 2023;18(1):e0279450. DOI: 10.1371/journal.pone.0279450Ward M., O’Toole S., Abu Saadeh F., Marchocki Z., Ibrahim E., Martin F. et al. Mechanisms of cancer associated thrombosis in gynaecological cancer patients-tumour or treatment effect? [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/mechanisms-of-cancer-associated-thrombosis-in-gynaecologicalcancer-patients-tumour-or-treatment-effect/. Accessed April 20, 2024.Ward M., O’Toole S., Abu Saadeh F., Marchocki Z., Ibrahim E., Martin F. et al. Mechanisms of cancer associated thrombosis in gynaecological cancer patients-tumour or treatment effect? [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/mechanisms-of-cancer-associated-thrombosis-in-gynaecologicalcancer-patients-tumour-or-treatment-effect/. Accessed April 20, 2024.Menter D.G., Tucker S.C., Kopetz S., Sood A.K., Crissman J.D., Honn K.V. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev. 2014;33(1):231–69. DOI: 10.1007/s10555-014-9498-0Menter D.G., Tucker S.C., Kopetz S., Sood A.K., Crissman J.D., Honn K.V. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev. 2014;33(1):231–69. DOI: 10.1007/s10555-014-9498-0Ward M., Kane L., Lochrin S., Ovaere C., O’Gorman C., O’Connor R. et al. Platelet and immune cell cloaking of circulating tumour cells [CTCs] in breast and ovarian cancer [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/platelet-and-immune-cellcloaking-of-circulating-tumour-cells-ctcs-in-breast-and-ovariancancer/. Accessed April 20, 2024.Ward M., Kane L., Lochrin S., Ovaere C., O’Gorman C., O’Connor R. et al. Platelet and immune cell cloaking of circulating tumour cells [CTCs] in breast and ovarian cancer [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/platelet-and-immune-cellcloaking-of-circulating-tumour-cells-ctcs-in-breast-and-ovariancancer/. Accessed April 20, 2024.Canonico M.E., Santoro C., Avvedimento M., Giugliano G., Mandoli G.E., Prastaro M. et al. Venous thromboembolism and cancer: A comprehensive review from pathophysiology to novel treatment. Biomolecules. 2022;12(2):259. DOI: 10.3390/biom12020259Canonico M.E., Santoro C., Avvedimento M., Giugliano G., Mandoli G.E., Prastaro M. et al. Venous thromboembolism and cancer: A comprehensive review from pathophysiology to novel treatment. Biomolecules. 2022;12(2):259. DOI: 10.3390/biom12020259Kim A.S., Khorana A.A., McCrae K.R. Mechanisms and biomarkers of cancer-associated thrombosis. Transl. Res. 2020;225:33–53. DOI: 10.1016/j.trsl.2020.06.012Kim A.S., Khorana A.A., McCrae K.R. Mechanisms and biomarkers of cancer-associated thrombosis. Transl. Res. 2020;225:33–53. DOI: 10.1016/j.trsl.2020.06.012Darwish I., Kantarcioglu B., Darki A., Siddiqui F., Iqbal O., Hoppensteadt D., Fareed J. The role of selectins in development of acute pulmonary embolism in cancer patients. [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/the-role-ofselectins-in-development-of-acute-pulmonary-embolism-in-cancerpatients/. Accessed April 20, 2024Darwish I., Kantarcioglu B., Darki A., Siddiqui F., Iqbal O., Hoppensteadt D., Fareed J. The role of selectins in development of acute pulmonary embolism in cancer patients. [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/the-role-ofselectins-in-development-of-acute-pulmonary-embolism-in-cancerpatients/. Accessed April 20, 2024Menter D.G., Afshar-Kharghan V., Shen J.P., Martch S.L., Maitra A., Kopetz S., Honn K.V., Sood A.K. Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. Cancer Metastasis Rev. 2022;41(1):147–172. DOI: 10.1007/s10555-022-10019-5Menter D.G., Afshar-Kharghan V., Shen J.P., Martch S.L., Maitra A., Kopetz S., Honn K.V., Sood A.K. Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. Cancer Metastasis Rev. 2022;41(1):147–172. DOI: 10.1007/s10555-022-10019-5Hisada Y., Geddings J.E., Ay C., Mackman N. Venous thrombosis and cancer: from mouse models to clinical trials. J. Thromb. Haemost. 2015;13(8):1372–82. DOI: 10.1111/jth.13009Hisada Y., Geddings J.E., Ay C., Mackman N. Venous thrombosis and cancer: from mouse models to clinical trials. J. Thromb. Haemost. 2015;13(8):1372–82. DOI: 10.1111/jth.13009Schwameis R., Grimm C., Brodowicz T., Petru E., Hefler-Frischmuth K., Staudigl C.et al. Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma. Sci. Rep. 2016;6:33757. DOI: 10.1038/srep33757Schwameis R., Grimm C., Brodowicz T., Petru E., Hefler-Frischmuth K., Staudigl C.et al. Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma. Sci. Rep. 2016;6:33757. DOI: 10.1038/srep33757Oto J., Mc Cormack B., Tomás-Pérez S., Fernández-Pardo A., González-Cantó E., Cana F.et al. Neutrophil activation markers as novel biomarkers for advanced stages of high-grade serous ovarian cancer [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/neutrophil-activation-markers-as-novel-biomarkers-foradvanced-stages-of-high-grade-serous-ovarian-cancer/. Accessed April 20, 2024.Oto J., Mc Cormack B., Tomás-Pérez S., Fernández-Pardo A., González-Cantó E., Cana F.et al. Neutrophil activation markers as novel biomarkers for advanced stages of high-grade serous ovarian cancer [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/neutrophil-activation-markers-as-novel-biomarkers-foradvanced-stages-of-high-grade-serous-ovarian-cancer/. Accessed April 20, 2024.Shinn E.H., Lenihan D.J., Urbauer D.L., Basen-Engquist K.M., Valentine A., Palmero L. et al. Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev. 2013;22(11):2102–9. DOI: 10.1158/1055-9965.EPI-13-0625Shinn E.H., Lenihan D.J., Urbauer D.L., Basen-Engquist K.M., Valentine A., Palmero L. et al. Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev. 2013;22(11):2102–9. DOI: 10.1158/1055-9965.EPI-13-0625Barber E.L., Clarke-Pearson D.L. Prevention of venous thromboembolism in gynecologic oncology surgery. Gynecol. Oncol. 2017; 144(2):420-427. DOI: 10.1016/j.ygyno.2016.11.036Barber E.L., Clarke-Pearson D.L. Prevention of venous thromboembolism in gynecologic oncology surgery. Gynecol. Oncol. 2017; 144(2):420-427. DOI: 10.1016/j.ygyno.2016.11.036Wiegers H., Beenen L., Schaafsma M., Middeldorp S., Hutten B., Mom S., Scheres L. Pre-surgical ovarian vein thrombosis in women with ovarian malignancies as predictor of pulmonary embolism [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/pre-surgical-ovarian-vein-thrombosis-in-women-withovarian-malignancies-as-predictor-of-pulmonary-embolism/. Accessed April 20, 2024.Wiegers H., Beenen L., Schaafsma M., Middeldorp S., Hutten B., Mom S., Scheres L. Pre-surgical ovarian vein thrombosis in women with ovarian malignancies as predictor of pulmonary embolism [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/pre-surgical-ovarian-vein-thrombosis-in-women-withovarian-malignancies-as-predictor-of-pulmonary-embolism/. Accessed April 20, 2024.Sermsathanasawadi N., Thangrod R., Hongku K., Wongwanit C., Ruangsetakit C., Chinsakchai K. et al. Prevalence of perioperative asymptomatic proximal deep vein thrombosis in Thai gynecologic cancer patients. J. Med. Assoc. Thai. 2014;97(2):153–8. PMID: 24765892.Sermsathanasawadi N., Thangrod R., Hongku K., Wongwanit C., Ruangsetakit C., Chinsakchai K. et al. Prevalence of perioperative asymptomatic proximal deep vein thrombosis in Thai gynecologic cancer patients. J. Med. Assoc. Thai. 2014;97(2):153–8. PMID: 24765892.Kong T.W., Ryu H.S., Kim S.C., Enomoto T., Li J., Kim K.H. et al. Asian Society of Gynecologic Oncology International Workshop 2018. J. Gynecol Oncol. 2019;30(2):e39. DOI: 10.3802/jgo.2019.30.e39Kong T.W., Ryu H.S., Kim S.C., Enomoto T., Li J., Kim K.H. et al. Asian Society of Gynecologic Oncology International Workshop 2018. J. Gynecol Oncol. 2019;30(2):e39. DOI: 10.3802/jgo.2019.30.e39Matsuo K., Hasegawa K., Yoshino K., Murakami R., Hisamatsu T., Stone R.L. et al. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. Eur. J. Cancer. 2015;51(14):1978–88. DOI: 10.1016/j.ejca.2015.07.012Matsuo K., Hasegawa K., Yoshino K., Murakami R., Hisamatsu T., Stone R.L. et al. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. Eur. J. Cancer. 2015;51(14):1978–88. DOI: 10.1016/j.ejca.2015.07.012Shah S., Dhamane A., Ferri M., Bruette R., Noxon V., Liu X., Jiang J., Luo X.. Factors associated with anticoagulant treatment initiation among venous thromboembolism patients with cancer [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/factors-associated-with-anticoagulant-treatment-initiationamong-venous-thromboembolism-patients-with-cancer/. Accessed April 20, 2024.Shah S., Dhamane A., Ferri M., Bruette R., Noxon V., Liu X., Jiang J., Luo X.. Factors associated with anticoagulant treatment initiation among venous thromboembolism patients with cancer [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/factors-associated-with-anticoagulant-treatment-initiationamong-venous-thromboembolism-patients-with-cancer/. Accessed April 20, 2024.Zhang W., Liu X., Cheng H., Yang Z., Zhang G. Risk factors and treatment of venous thromboembolism in perioperative patients with ovarian cancer in China. Medicine (Baltimore). 2018;97(31):e11754. DOI: 10.1097/MD.0000000000011754Zhang W., Liu X., Cheng H., Yang Z., Zhang G. Risk factors and treatment of venous thromboembolism in perioperative patients with ovarian cancer in China. Medicine (Baltimore). 2018;97(31):e11754. DOI: 10.1097/MD.0000000000011754Guman N., Wiegers H., Schaafsma M., Mulder F., Mom S., van Es N. Performance of the Thrombogyn and Khorana scores for prediction of venous thromboembolism in ovarian cancer patients after major surgery [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/performance-of-the-thrombogyn-and-khorana-scoresfor-prediction-of-venous-thromboembolism-in-ovarian-cancerpatients-after-major-surgery/. Accessed April 20, 2024.Guman N., Wiegers H., Schaafsma M., Mulder F., Mom S., van Es N. Performance of the Thrombogyn and Khorana scores for prediction of venous thromboembolism in ovarian cancer patients after major surgery [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/performance-of-the-thrombogyn-and-khorana-scoresfor-prediction-of-venous-thromboembolism-in-ovarian-cancerpatients-after-major-surgery/. Accessed April 20, 2024.Donadini M., Squizzato A., Ferrazzi P., Maggioni S., Sacco C., Lodigiani C. Pharmacological thromboprophylaxis to prevent venous thromboembolism in ambulatory patients with cancer undergoing antineoplastic drugs in real world clinical practice: a cohort study [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/pharmacological-thromboprophylaxis-to-prevent-venousthromboembolism-in-ambulatory-patients-with-cancer-undergoingantineoplastic-drugs-in-real-world-clinical-practice-a-cohort-study/. Accessed April 20, 2024.Donadini M., Squizzato A., Ferrazzi P., Maggioni S., Sacco C., Lodigiani C. Pharmacological thromboprophylaxis to prevent venous thromboembolism in ambulatory patients with cancer undergoing antineoplastic drugs in real world clinical practice: a cohort study [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/pharmacological-thromboprophylaxis-to-prevent-venousthromboembolism-in-ambulatory-patients-with-cancer-undergoingantineoplastic-drugs-in-real-world-clinical-practice-a-cohort-study/. Accessed April 20, 2024.Vivas Y., Medina E., Abreu E., Rezende S., RIbeiro D. Khorana score as a predictor of thrombotic risk in outpatients with malignant neoplasms [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/khorana-score-as-a-predictor-of-thrombotic-riskin-outpatients-with-malignant-neoplasms/. Accessed April 20, 2024.Vivas Y., Medina E., Abreu E., Rezende S., RIbeiro D. Khorana score as a predictor of thrombotic risk in outpatients with malignant neoplasms [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/khorana-score-as-a-predictor-of-thrombotic-riskin-outpatients-with-malignant-neoplasms/. Accessed April 20, 2024.Lyman G.H., Carrier M., Ay C., Di Nisio M., Hicks L.K., Khorana A.A. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–974. DOI: 10.1182/bloodadvances.2020003442Lyman G.H., Carrier M., Ay C., Di Nisio M., Hicks L.K., Khorana A.A. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–974. DOI: 10.1182/bloodadvances.2020003442Liu M., Wang G., Li Y., Wang H., Liu H., Guo N. et al. Effi cacy and safety of thromboprophylaxis in cancer patients: a systematic review and meta-analysis. Ther. Adv. Med. Oncol. 2020;12:1758835920907540. DOI: 10.1177/1758835920907540Liu M., Wang G., Li Y., Wang H., Liu H., Guo N. et al. Effi cacy and safety of thromboprophylaxis in cancer patients: a systematic review and meta-analysis. Ther. Adv. Med. Oncol. 2020;12:1758835920907540. DOI: 10.1177/1758835920907540Park J.Y. The role of direct oral anticoagulants in venous thromboembolic disease in gynecologic cancer. .J Gynecol. Oncol. 2020;31(1):e40. DOI: 10.3802/jgo.2020.31.e40Park J.Y. The role of direct oral anticoagulants in venous thromboembolic disease in gynecologic cancer. .J Gynecol. Oncol. 2020;31(1):e40. DOI: 10.3802/jgo.2020.31.e40Muñoz Martín A.J., Font Puig C., Navarro Martín L.M., Borrega García P., Martín Jiménez M.; Spanish Society for Medical Oncology. Clinical guide SEOM on venous thromboembolism in cancer patients. Clin. Transl. Oncol. 2014;16(12):1079–90. DOI: 10.1007/s12094-014-1238-yMuñoz Martín A.J., Font Puig C., Navarro Martín L.M., Borrega García P., Martín Jiménez M.; Spanish Society for Medical Oncology. Clinical guide SEOM on venous thromboembolism in cancer patients. Clin. Transl. Oncol. 2014;16(12):1079–90. DOI: 10.1007/s12094-014-1238-yPachón V., Trujillo-Santos J., Domènech P., Gallardo E., Font C., González Porras J.R. et al. Cancer-associated thrombosis: beyond clinical practice guidelines-a multidisciplinary (SEMI-SEOMSETH) Expert Consensus. TH Open. 2018;2(4):e373–e386. DOI: 10.1055/s-0038-1675577Pachón V., Trujillo-Santos J., Domènech P., Gallardo E., Font C., González Porras J.R. et al. Cancer-associated thrombosis: beyond clinical practice guidelines-a multidisciplinary (SEMI-SEOMSETH) Expert Consensus. TH Open. 2018;2(4):e373–e386. DOI: 10.1055/s-0038-1675577Baaten C.C.F.M.J., Moenen F.C.J.I., Henskens Y.M.C., Swieringa F., Wetzels R.J.H., van Oerle R., Heijnen H.F.G. et al. Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer patients undergoing chemotherapy. Hae ma tologica. 2018;103(9):1557–1567. DOI: 10.3324/haematol.2017.185165Baaten C.C.F.M.J., Moenen F.C.J.I., Henskens Y.M.C., Swieringa F., Wetzels R.J.H., van Oerle R., Heijnen H.F.G. et al. Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer patients undergoing chemotherapy. Hae ma tologica. 2018;103(9):1557–1567. DOI: 10.3324/haematol.2017.185165Yuk J.S., Lee B., Kim K., Kim M.H., Seo Y.S., Hwang S.O. et al. Incidence and risk of venous thromboembolism according to primary treatment type in women with endometrial cancer: a populationbased study. BMC Cancer. 2021;21(1):1166. DOI: 10.1186/s12885-021-08853-xYuk J.S., Lee B., Kim K., Kim M.H., Seo Y.S., Hwang S.O. et al. Incidence and risk of venous thromboembolism according to primary treatment type in women with endometrial cancer: a populationbased study. BMC Cancer. 2021;21(1):1166. DOI: 10.1186/s12885-021-08853-xWright J.D., Chen L., Jorge S., Burke W.M., Tergas A.I., Hou J.Y. et al. Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery. Gynecol. Oncol. 2016; 141(3):531–537. DOI: 10.1016/j.ygyno.2016.03.023Wright J.D., Chen L., Jorge S., Burke W.M., Tergas A.I., Hou J.Y. et al. Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery. Gynecol. Oncol. 2016; 141(3):531–537. DOI: 10.1016/j.ygyno.2016.03.023Faruqi U., Darroch R., Verma H., Bahra G., Flynn M., Danaee A. The role of anticoagulation in the management of tumour thrombosis: A single centre retrospective study [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/the-role-of-anticoagulation- in-the-management-of-tumour-thrombosis-a-single-centreretrospective-study/. Accessed April 20, 2024.Faruqi U., Darroch R., Verma H., Bahra G., Flynn M., Danaee A. The role of anticoagulation in the management of tumour thrombosis: A single centre retrospective study [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/the-role-of-anticoagulation- in-the-management-of-tumour-thrombosis-a-single-centreretrospective-study/. Accessed April 20, 2024.Osataphan S., Patell R., Chiasakul T., Khorana A.A., Zwicker J.I. Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis. Blood Adv. 2021;5(8):2055– 2062. DOI: 10.1182/bloodadvances.2020004118Osataphan S., Patell R., Chiasakul T., Khorana A.A., Zwicker J.I. Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis. Blood Adv. 2021;5(8):2055– 2062. DOI: 10.1182/bloodadvances.2020004118Ghenassia-Fouillet L., Morel A, Frappé P., Le Hello C., Lerche V., Sevestre M.A., Bertoletti L. Management of superficial venous thrombosis in unevaluated situations: cancer, severe renal impairment, pregnancy and post-partum. Phlebology. 2021;36(6):464–472. DOI: 10.1177/0268355520982456Ghenassia-Fouillet L., Morel A, Frappé P., Le Hello C., Lerche V., Sevestre M.A., Bertoletti L. Management of superficial venous thrombosis in unevaluated situations: cancer, severe renal impairment, pregnancy and post-partum. Phlebology. 2021;36(6):464–472. DOI: 10.1177/0268355520982456Poenou G., Toledano E., Helfer H., Plaisance L., Versini E., Diab N., Djennaoui S., Mahe I. Anticoagulant associated bleeding risk assessment model for cancer associated thrombosis patients: A systematic review [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/anticoagulant-associated-bleeding-riskassessment-model-for-cancer-associated-thrombosis-patients-asystematic-review/. Accessed April 20, 2024.Poenou G., Toledano E., Helfer H., Plaisance L., Versini E., Diab N., Djennaoui S., Mahe I. Anticoagulant associated bleeding risk assessment model for cancer associated thrombosis patients: A systematic review [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/anticoagulant-associated-bleeding-riskassessment-model-for-cancer-associated-thrombosis-patients-asystematic-review/. Accessed April 20, 2024.Hirmerová J., Šubrt I., Hajšmanová Z. The prevalence of thrombophilia in patients with cancer associated thromboembolism [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/the-prevalence-of-thrombophilia-in-patients-with-cancerassociated-thromboembolism/. Accessed April 20, 2024.Hirmerová J., Šubrt I., Hajšmanová Z. The prevalence of thrombophilia in patients with cancer associated thromboembolism [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/the-prevalence-of-thrombophilia-in-patients-with-cancerassociated-thromboembolism/. Accessed April 20, 2024.Haque F., Mnyama N., Adeniyi-zaccheus O., Wells R., Brown V., Maraveyas A. Safety and effi cacy of direct oral anticoagulant in elderly patients with cancer: real-world challenges [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/safetyand-efficacy-of-direct-oral-anticoagulant-in-elderly-patients-withcancer-real-world-challenges/. Accessed April 20, 2024.Haque F., Mnyama N., Adeniyi-zaccheus O., Wells R., Brown V., Maraveyas A. Safety and effi cacy of direct oral anticoagulant in elderly patients with cancer: real-world challenges [abstract]. [Electronic resource]. URL: https://abstracts.isth.org/abstract/safetyand-efficacy-of-direct-oral-anticoagulant-in-elderly-patients-withcancer-real-world-challenges/. Accessed April 20, 2024.Murofushi K.N., Tomita T., Ohnishi K., Nakai K., Akiyama A., Saida T. et al. Risk factors for venous thromboembolism induced by prolonged bed rest during interstitial brachytherapy for gynecological cancer: a retrospective study. Radiat. Oncol. 2021;16(1):121. DOI: 10.1186/s13014-021-01840-3Murofushi K.N., Tomita T., Ohnishi K., Nakai K., Akiyama A., Saida T. et al. Risk factors for venous thromboembolism induced by prolonged bed rest during interstitial brachytherapy for gynecological cancer: a retrospective study. Radiat. Oncol. 2021;16(1):121. DOI: 10.1186/s13014-021-01840-3HinchcliffE.M., Bednar E.M., Lu K.H., Rauh-Hain J.A. Disparities in gynecologic cancer genetics evaluation. Gynecol. Oncol. 2019;153(1):184–191. DOI: 10.1016/j.ygyno.2019.01.024HinchcliffE.M., Bednar E.M., Lu K.H., Rauh-Hain J.A. Disparities in gynecologic cancer genetics evaluation. Gynecol. Oncol. 2019;153(1):184–191. DOI: 10.1016/j.ygyno.2019.01.024Kostov S., Watrowski R., Kornovski Y., Dzhenkov D., Slavchev S., Ivanova Y., Yordanov A. hereditary gynecologic cancer syndromes — a narrative review. Onco. Targets Ther. 2022;15:381–405. DOI: 10.2147/OTT.S353054Kostov S., Watrowski R., Kornovski Y., Dzhenkov D., Slavchev S., Ivanova Y., Yordanov A. hereditary gynecologic cancer syndromes — a narrative review. Onco. Targets Ther. 2022;15:381–405. DOI: 10.2147/OTT.S353054Tang Y.H., Lin C.Y., Lai C.H. Development of new cancer treatment by identifying and focusing the genetic mutations or altered expression in gynecologic cancers. Genes (Basel). 2021;12(10):1593. DOI: 10.3390/genes12101593Tang Y.H., Lin C.Y., Lai C.H. Development of new cancer treatment by identifying and focusing the genetic mutations or altered expression in gynecologic cancers. Genes (Basel). 2021;12(10):1593. DOI: 10.3390/genes12101593Tang M., Cai J.H., Diao H.Y., Guo W.M., Yang X., Xing S. The progress of peptide vaccine clinical trials in gynecologic oncology. Hum. Vaccin. Immunother. 2022;18(5):2062982. DOI: 10.1080/21645515.2022.2062982Tang M., Cai J.H., Diao H.Y., Guo W.M., Yang X., Xing S. The progress of peptide vaccine clinical trials in gynecologic oncology. Hum. Vaccin. Immunother. 2022;18(5):2062982. DOI: 10.1080/21645515.2022.2062982Walsh M., Moore E.E., Moore H., Thomas S., Lune S.V., Zimmer D. et al. Use of viscoelastography in malignancy-associated coagulopathy and thrombosis: a review. Semin. Thromb. Hemost. 2019;45(4):354– 372. DOI: 10.1055/s-0039-1688497Walsh M., Moore E.E., Moore H., Thomas S., Lune S.V., Zimmer D. et al. Use of viscoelastography in malignancy-associated coagulopathy and thrombosis: a review. Semin. Thromb. Hemost. 2019;45(4):354– 372. DOI: 10.1055/s-0039-1688497Siddiqui F., Antic D., Tafur A., Bontekoe E., Hoppensteadt D., Gerotziafas G. et al. Thrombin generation profile in various lymphoma sub-groups and its augmentation by Andexanet Alfa. Clin. Appl. Thromb. Hemost. 2020;26:1076029620983466. DOI: 10.1177/1076029620983466Siddiqui F., Antic D., Tafur A., Bontekoe E., Hoppensteadt D., Gerotziafas G. et al. Thrombin generation profile in various lymphoma sub-groups and its augmentation by Andexanet Alfa. Clin. Appl. Thromb. Hemost. 2020;26:1076029620983466. DOI: 10.1177/1076029620983466Mauracher L.M., Posch F., Martinod K., Grilz E., Däullary T., Hell L. et al. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients. J. Thromb. Haemost. 2018;16(3):508–518. DOI: 10.1111/jth.13951Mauracher L.M., Posch F., Martinod K., Grilz E., Däullary T., Hell L. et al. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients. J. Thromb. Haemost. 2018;16(3):508–518. DOI: 10.1111/jth.13951Posch F., Thaler J., Zlabinger G.J., Königsbrügge O., Koder S., Zielinski C., Pabinger I., Ay C. Soluble vascular endothelial growth factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: results from the vienna cancer and thrombosis study (CATS). Clin. Cancer Res. 2016;22(1):200–6. DOI: 10.1158/1078-0432.CCR-14-3358. Epub 2015 Aug 24. PMID: 26302981Posch F., Thaler J., Zlabinger G.J., Königsbrügge O., Koder S., Zielinski C., Pabinger I., Ay C. Soluble vascular endothelial growth factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: results from the vienna cancer and thrombosis study (CATS). Clin. Cancer Res. 2016;22(1):200–6. DOI: 10.1158/1078-0432.CCR-14-3358. Epub 2015 Aug 24. PMID: 26302981Julia E.G., Nigel M. Recently identified factors that regulate hemostasis and thrombosis. Thromb. Haemost. 2014;111(4):570– 574. DOI:10.1160/TH13-10-0812Julia E.G., Nigel M. Recently identified factors that regulate hemostasis and thrombosis. Thromb. Haemost. 2014;111(4):570– 574. DOI:10.1160/TH13-10-0812

The authors declare that there are no conflicts of interest present.